Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC.RXRX · Entity 1008 | President and COO | November 15, 2024 | November 19, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RECURSION PHARMACEUTICALS, INC.
Report date November 15, 2024 · Filed November 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 506,852 |
Reported balance
After 2024-11-15 transaction · row 1
1 source rowRow 1 · 2024-11-15 · Tax withholding · Disposed 14,286 · Balance 506,852 F1: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2028-07-22 | Direct | 452,000 |
Reported balance
Holding disclosure · report date 2024-11-15 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 452,000 F2: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.55 · Expires 2033-02-01 | Direct | 434,122 |
Reported balance
Holding disclosure · report date 2024-11-15 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 434,122 F3: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.40 · Expires 2032-02-04 | Direct | 159,226 |
Reported balance
Holding disclosure · report date 2024-11-15 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 159,226 F4: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.40 · Expires 2032-02-04 | Direct | 4,784 |
Reported balance
Holding disclosure · report date 2024-11-15 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 4,784 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2030-12-30 | Direct | 150,000 |
Reported balance
Holding disclosure · report date 2024-11-15 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 150,000 F5: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.09 · Expires 2034-02-09 | Direct | 447,917 |
Reported balance
Holding disclosure · report date 2024-11-15 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 447,917 F6: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F2: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date.
F3: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F4: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F5: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date.
F6: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2022 Filed Feb 23, 2022 00:58 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-22-011969 · doc4.xml · derivative · entry 2 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 692,500 Underlying: Class A Common Stock · 692,500 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (148th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 00:58 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 16,000 | $1.06 | $16,960.00 |
DisclosureSEC source: 0001209191-22-011969 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 11:04 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-22-010496 · doc4.xml · derivative · entry 2 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 708,500 Underlying: Class A Common Stock · 708,500 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (148th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 11:04 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 4,000 | $1.06 | $4,240.00 |
DisclosureSEC source: 0001209191-22-010496 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:05 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 4,784 | $0.00 Strike: $11.40 | $0.00 |
DisclosureSEC source: 0001209191-22-007911 · doc4.xml · derivative · entry 5 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,784 Underlying: Class A Common Stock · 4,784 shares Expires 2032-02-04 Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:05 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 159,226 | $0.00 Strike: $11.40 | $0.00 |
DisclosureSEC source: 0001209191-22-007911 · doc4.xml · derivative · entry 4 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,226 Underlying: Class A Common Stock · 159,226 shares Expires 2032-02-04 F4 · derivative.exercise_date: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:05 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 828 | $11.40 | $9,439.20 |
DisclosureSEC source: 0001209191-22-007911 · doc4.xml · nonDerivative · entry 3 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,518 Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:05 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 2,392 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007911 · doc4.xml · nonDerivative · entry 2 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,346 F3 · kind: This RSU vested immediately upon the grant date. Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:05 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 79,613 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007911 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,954 F1 · kind: This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2022 and every three months thereafter. F2 · balance_after: Includes 841 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on November 22, 2021. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 23:00 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 300 | $19.78 | $5,933.01 |
DisclosureSEC source: 0001209191-21-070631 · doc4.xml · nonDerivative · entry 3 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,500 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F4 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $19.69 to $19.93 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 23:00 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 1,040 | $19.17 | $19,932.85 |
DisclosureSEC source: 0001209191-21-070631 · doc4.xml · nonDerivative · entry 2 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,800 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F3 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $18.69 to $19.55 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 23:00 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 1,160 | $18.09 | $20,982.54 |
DisclosureSEC source: 0001209191-21-070631 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,840 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $17.63 to $18.53 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| November 18, 2021 Filed Nov 23, 2021 01:23 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 702 | $19.20 | $13,479.45 |
DisclosureSEC source: 0001209191-21-066261 · doc4.xml · nonDerivative · entry 2 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F3 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $19.13 to $19.26 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| November 18, 2021 Filed Nov 23, 2021 01:23 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 1,798 | $18.81 | $33,828.47 |
DisclosureSEC source: 0001209191-21-066261 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,702 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $18.10 to $19.06 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0001209191-21-028036 · doc4.xml · derivative · entry 6 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Class A Common Stock · 150,000 shares Expires 2030-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionStock Option (Right to Buy) · Derivative | 712,500 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-21-028036 · doc4.xml · derivative · entry 5 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 712,500 Underlying: Class A Common Stock · 712,500 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (148th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0001209191-21-028036 · doc4.xml · derivative · entry 4 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2030-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionStock Option (Right to Buy) · Derivative | 712,500 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-21-028036 · doc4.xml · derivative · entry 3 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 712,500 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (148th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | OtherClass A Common Stock | 52,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028036 · doc4.xml · nonDerivative · entry 2 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 F1 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | OtherCommon Stock | 52,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028036 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.